Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the short-term effects of the antimalarial
medication, hydroxychloroquine (HCQ), compared with placebo using frequently sampled
intravenous glucose tolerance testing (FSIGTT) methodology to study changes in insulin
secretion and glucose tolerance in subjects at risk for developing Type 2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pittsburgh
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)